This is the authors' abstract. We don't add key points for this paper.
Crystallization is the primary process used to purify synthetic drug substances and intermediates as well as to control bulk properties, including particle size, surface area, and flowability. Accordingly, new or improved tools to aid crystallization design are of central importance to drug development. In this Perspective, we provide a brief review of the state of the art, identify current challenges, and highlight key opportunities within different aspects of crystallization process development for synthetic pharmaceutical compounds.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Cote et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: